Literature DB >> 25409376

ROS1--targeting the one percent in lung cancer.

Kathryn A Gold1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25409376     DOI: 10.1056/NEJMe1411319

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

1.  Downregulation of ROS1 enhances the therapeutic efficacy of arsenic trioxide in acute myeloid leukemia cell lines.

Authors:  Jun Li
Journal:  Oncol Lett       Date:  2018-04-10       Impact factor: 2.967

2.  Beyond KRAS: Practical Molecular Targets in Pancreatic Adenocarcinoma.

Authors:  Albert Grinshpun; Yonaton Zarbiv; Jason Roszik; Vivek Subbiah; Ayala Hubert
Journal:  Case Rep Oncol       Date:  2019-01-04

Review 3.  PET in the management of locally advanced and metastatic NSCLC.

Authors:  Willem Grootjans; Lioe-Fee de Geus-Oei; Esther G C Troost; Eric P Visser; Wim J G Oyen; Johan Bussink
Journal:  Nat Rev Clin Oncol       Date:  2015-04-28       Impact factor: 66.675

4.  ROS1 copy number alterations are frequent in non-small cell lung cancer.

Authors:  Sergi Clavé; Javier Gimeno; Ana M Muñoz-Mármol; Joana Vidal; Noemí Reguart; Enric Carcereny; Lara Pijuan; Sílvia Menéndez; Álvaro Taus; José Luís Mate; Sergio Serrano; Joan Albanell; Blanca Espinet; Edurne Arriola; Marta Salido
Journal:  Oncotarget       Date:  2016-02-16

Review 5.  Cardiovascular Complications Associated with Contemporary Lung Cancer Treatments.

Authors:  Kazuhiro Sase; Yasuhito Fujisaka; Masaaki Shoji; Mikio Mukai
Journal:  Curr Treat Options Oncol       Date:  2021-06-10

6.  Beyond epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) testing in advanced non-small cell lung cancer: Is the picture as "ROS1" as it appears?

Authors:  Navneet Singh
Journal:  Lung India       Date:  2017 Sep-Oct
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.